Literature DB >> 31782076

Updates on Botulinum Neurotoxins in Dermatology.

Edith Hanna1, Kucy Pon2.   

Abstract

Being the most popular non-surgical cosmetic procedure, botulinum neurotoxin (BoNT) injections are increasingly of interest to all cosmetic practitioners across the globe. This article serves to update readers on the new botulinum toxins that are currently in development or close to market in the USA and Canada, including daxibotulinumtoxin A, prabotulinumtoxin A, letibotulinumtoxin A, and botulinum toxin E. Despite having relatively similar characteristics and equivalent clinical efficacies, these neurotoxins manifest a multitude of unique potential advantages that will be explored in this review, including but not limited to a longer duration of action, the absence of animal-derived components or human albumin, and a rapid onset with short duration of action.

Entities:  

Year:  2020        PMID: 31782076     DOI: 10.1007/s40257-019-00482-2

Source DB:  PubMed          Journal:  Am J Clin Dermatol        ISSN: 1175-0561            Impact factor:   7.403


  5 in total

Review 1.  Causes of Botulinum Toxin Treatment Failure.

Authors:  Valentina Shtefan; James Fletcher; Olga Anna Duclos
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-06-07

Review 2.  The "Visible" Muscles on Ultrasound Imaging Make Botulinum Toxin Injection More Precise: A Systematic Review.

Authors:  Zhijin Li; Yanlong Yang; Nanze Yu; Wenzhe Zhou; Zirong Li; Yuming Chong; Yuwei Zhang; Hayson Chenyu Wang; Cheng Chen; Xiao Long; Xiaojun Wang
Journal:  Aesthetic Plast Surg       Date:  2021-08-02       Impact factor: 2.326

Review 3.  FDA Approvals and Consensus Guidelines for Botulinum Toxins in the Treatment of Dystonia.

Authors:  Lauren L Spiegel; Jill L Ostrem; Ian O Bledsoe
Journal:  Toxins (Basel)       Date:  2020-05-17       Impact factor: 4.546

Review 4.  Botulinum Toxin: An Update on Pharmacology and Newer Products in Development.

Authors:  Supriyo Choudhury; Mark R Baker; Suparna Chatterjee; Hrishikesh Kumar
Journal:  Toxins (Basel)       Date:  2021-01-14       Impact factor: 4.546

5.  Outcomes of a regional variant of botulinum toxin type A in the treatment of essential blepharospasm and hemifacial spasms: A retrospective study.

Authors:  V Maneksha; Sabyasachi Chakrabarty; Meghana Tanwar; Madhavi Ramanatha Pillai
Journal:  Indian J Ophthalmol       Date:  2021-10       Impact factor: 1.848

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.